(Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public Omega Constellation Pink Face
Chimerix's lead product candidate, brincidofovir (CMX001), is an oral nucleotide analog that has shown broad spectrum antiviral activity against all five families of dsDNA viruses that affect humans, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex viruses. In addition, Chimerix has an active discovery program leveraging its lipid technology and the Chimerix Chemical Omega Seamaster Professional 300m Movement
Chimerix, Inc. (CMRX) Taps New CEO After Moch Resignation IntelliPharmaCeutics Files Preliminary Base Shelf Prospectus And Shelf Registration Statement
offering and the expected proceeds therefrom. Among the factors that could cause actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Chimerix's business and finances in general, and the other risks described in Chimerix's annual report on Form 10 K for the year ended December 31, 2013, quarterly report on Form 10 Q for the quarter ended March 31, 2014 and other filings with the SEC. Schepers
In addition to historical facts, this press release contains forward looking statements that involve a number of risks and uncertainties such as those, among others, relating to Chimerix's expectations regarding the completion, timing and size of its public Omega Speedmaster Moonwatch Wrist
Executive Director, Investor Relations andHelp employers find you! Check out all the .
Morgan Stanley Co. and Canaccord Genuity Inc. are acting as co managers for the offering.
Library, both focusing on viral targets in areas of high unmet medical need.
Chimerix, Inc. (CMRX) Looks To Rally Up $60 Million Partly To Pay For Drug Trial With Josh Hardy AstraZeneca PLC (AZN) Shares Back On Rise Amid Fresh Bid Speculation
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Chimerix Inc Prices Public Offering Of Common Stock
Chimerix, Inc. (CMRX) Regains Worldwide Rights To CMX157 Gilead Sciences, Inc. (GILD) Will Buy Back Another $5 Billion Of Shares
The securities described above are being offered by Chimerix pursuant to a shelf registration statement (including a prospectus) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on May 16, 2014. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866 803 9204.
offering of 7,300,000 shares of Omega Speedmaster Titanium Blue Dial its common stock at a price to the public of $14.22 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $103.8 million. The offering is expected to close on or about May 27, 2014, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Why Everyone Has A Stake In The Chimerix, Inc. (CMRX) Drug Offered To Dying Boy Ablynx (ABLYF) Release: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law")
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. Chimerix was founded in 2000 based on the promise of its proprietary lipid technology to unlock the antiviral potential of some of the most broad spectrum antivirals by enhancing their antiviral activity and safety profiles in convenient, orally administered dosing regimens.
Did Chimerix, Inc. (CMRX) Set A Bad Example For Biopharma? XenoPort, Inc. (XNPT) To Mail Letter To Stockholders
Nike Dri Fit Long Sleeve Hoodie
Omega Seamaster With Date
Omega Green Watch
Omega Seamaster Edizione Venezia
Omega Seamaster Rose Gold Women's Automatic Watch
Omega Watches James Bond Skyfall
Nike Hoodie Kids
Omega Watches Seamaster Planet Ocean
Omega Constellation Ladies 27mm
Omega Seamaster Quartz Vintage
Nike Sweaters Windbreaker
Nike Long Sleeve Dri Fit Mens
Omega Speedmaster Day Date Discontinued
Omega Speedmaster 57 Titanium
Nike Hoodie Grey